A phase I, multiple-dose trial of IMO 3100 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2011
At a glance
- Drugs IMO 3100 (Primary)
- Indications Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions
- 05 Apr 2011 Results have been presented at the Keystone Symposia meeting "Immunoregulatory Networks" according to an Idera Pharmaceuticals media release; results were also summarised in the media release.
- 15 Feb 2011 Status changed from planning to completed.
- 03 Feb 2010 New trial record